August 16, 2017 4:55 PM ET

Pharmaceuticals

Company Overview of Sucampo Pharmaceuticals, Inc.

Executive Profile

Peter S. Greenleaf

AgeTotal Calculated CompensationThis person is connected to 4 Board Members in 4 different organizations across 9 different industries.

See Board Relationships
47$4,339,094
As of Fiscal Year 2016

Background

Mr. Peter S. Greenleaf has been the Chairman and Chief Executive Officer of Sucampo Pharmaceuticals, Inc. since January 1, 2016 and March 03, 2014 respectively. Mr. Greenleaf has been an Executive Director at Sucampo Pharmaceuticals, Inc. since March 03, 2014. He served as Chief Executive Officer of Histogenics Corporation from June 10, 2013 to February 28, 2014 and served as its President. He served as President of MedImmune, LLC (also known as MedImmune, Inc.). He ...

Corporate Headquarters

805 King Farm Boulevard
Rockville, Maryland 20850

United States

Phone: 301-961-3400
Fax: 301-961-3440

Board Members Memberships

Director
2014-Present
Chairman & CEO
2016-Present
Non-Employee Director
2017-Present
Director

Education

MBA
Saint Joseph's University
BS
Western Connecticut State University

Other Affiliations

Annual Compensation

Salary$652,991
Total Annual Compensation$652,991

Stocks Options

All Other Compensation$9,000
Exercised Options$200,000
Exercised Options Value$2,018,801
Exercisable Options$452,500
Exercisable Options Value$2,283,000
Unexercisable Options$977,500
Unexercisable Options Value$2,283,000
Total Value of Options$6,584,801
Total Number of Options$1,630,000

Total Compensation

Total Annual Cash Compensation$1,277,504
Total Short Term Compensation$652,991
Other Long Term Compensation$9,000
Total Calculated Compensation$4,339,094
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Mark R. Baker J.D.Chief Executive Officer and Director
Progenics Pharmaceuticals, Inc.
$646.8K
Gary S. Jacob Ph.D.Chairman of the Board, CEO & President
Synergy Pharmaceuticals Inc.
$844.0K
Craig A. Wheeler Chief Executive Officer, President and Executive Director
Momenta Pharmaceuticals, Inc.
$689.2K
A. J. Kazimi MBAFounder, Chairman, Chief Executive Officer and President
Cumberland Pharmaceuticals Inc.
$698.0K
John Anthony Sedor Chairman and Chief Executive Officer
Pernix Therapeutics Holdings, Inc.
$805.7K
Compensation as of Fiscal Year 2016.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Sucampo Pharmaceuticals, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.